Trial · NCT00544869
Adverse events120
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 120
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Stopped at End of Treatment Period 1 | 0 | 36 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Continued at 15 mg/Day | 1 | 13 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Dose Escalated to 30 mg/Day | 0 | 2 | 0 |
| other | Cardiac Failure | Cardiac disorders | Stopped at End of Treatment Period 1 | 0 | 36 | 0 |
| other | Cardiac Failure | Cardiac disorders | Continued at 15 mg/Day | 1 | 13 | 1 |
| other | Cardiac Failure | Cardiac disorders | Dose Escalated to 30 mg/Day | 0 | 2 | 0 |
| other | Ventricular Extrasystoles | Cardiac disorders | Stopped at End of Treatment Period 1 | 0 | 36 | 0 |
| other | Ventricular Extrasystoles | Cardiac disorders | Continued at 15 mg/Day | 2 | 13 | 2 |
| other | Ventricular Extrasystoles | Cardiac disorders | Dose Escalated to 30 mg/Day | 0 | 2 | 0 |
| other | Ventricular Tachycardia | Cardiac disorders | Stopped at End of Treatment Period 1 | 4 | 36 | 4 |
| other | Ventricular Tachycardia | Cardiac disorders | Continued at 15 mg/Day | 0 | 13 | 0 |
| other | Ventricular Tachycardia | Cardiac disorders | Dose Escalated to 30 mg/Day | 1 | 2 | 1 |
| other | Abdominal Pain | Gastrointestinal disorders | Stopped at End of Treatment Period 1 | 1 | 36 | 1 |
| other | Abdominal Pain | Gastrointestinal disorders | Continued at 15 mg/Day | 1 | 13 | 2 |
| other | Abdominal Pain | Gastrointestinal disorders | Dose Escalated to 30 mg/Day | 0 | 2 | 0 |
| other | Constipation | Gastrointestinal disorders | Stopped at End of Treatment Period 1 | 5 | 36 | 5 |
| other | Constipation | Gastrointestinal disorders | Continued at 15 mg/Day | 0 | 13 | 0 |
| other | Constipation | Gastrointestinal disorders | Dose Escalated to 30 mg/Day | 0 | 2 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Stopped at End of Treatment Period 1 | 1 | 36 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Continued at 15 mg/Day | 2 | 13 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00544869/events